COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497

Major therapeutic developments and current challenges in advanced melanoma

Sullivan, R. J., & Flaherty, K. T. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12698 · Cited by 24

Precision Oncology—The Quest for Evidence

Soldatos, T. G., Kaduthanam, S., & Jackson, D. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9030043 · Cited by 24

BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases

Grigore, F., Yang, H., Hanson, N. D., VanBrocklin, M. W., Sarver, A. L., & Robinson, J. P. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.006 · Cited by 23

Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition

Ji, Z., Njauw, C.-N. J., Guhan, S. M., Kumar, R., Reddy, B. Y., Rajadurai, A., Flaherty, K. T., & Tsao, H. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.041 · Cited by 24

Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor Prognosis

Bahri, R., Kiss, O., Prise, I. E., Garcia‐Rodriguez, K. M., Atmoko, H., Martínez-Gómez, J. M., Levesque, M. P., Dummer, R., Smith, M. P., Wellbrock, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861545 · Cited by 24

Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents

Tsai, W.-B., Long, Y., Park, J.-R., Chang, J. T., Liu, H., Rodriguez‐Canales, J., Savaraj, N., Feun, L. G., Davies, M. A., Wistuba, I. I., et al. (2015) · Oncogene · doi:10.1038/onc.2015.237 · Cited by 24

Human skin cancer stem cells: a tale of mice and men

Colmont, C. S., Harding, K. G., Piguet, V., & Patel, G. K. (2012) · Experimental Dermatology · doi:10.1111/j.1600-0625.2012.01533.x · Cited by 24

MERTK as a novel therapeutic target in head and neck cancer

von Mäßenhausen, A., Sanders, C., Thewes, B., Deng, M. C.-H. K., Queisser, A., Vogel, W., Kristiansen, G., Duensing, S. M., Schröck, A., Bootz, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8724 · Cited by 24

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies

Manole, S., Richards, E. J., & Meyer, A. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0123 · Cited by 25

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

Xue, G., Kohler, R. S., Tang, F., Hynx, D., Wang, Y., Orso, F., Prêtre, V., Ritschard, R., Hirschmann, P., Cron, P. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18213 · Cited by 25

Modelling bistable tumour population dynamics to design effective treatment strategies

Akhmetzhanov, A. R., Kim, J. W., Sullivan, R. J., Beckman, R. A., Tamayo, P., & Yeang, C. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.05.005 · Cited by 24

Localized Intercellular Transfer of Ephrin-As by Trans-endocytosis Enables Long-Term Signaling

Valenzuela, J. I., & Perez, F. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.11.013 · Cited by 24

The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma

John, L., & Cowey, C. L. (2015) · Dermatology and Therapy · doi:10.1007/s13555-015-0080-7 · Cited by 23

Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf

Ahn, J.-H., & Lee, M. (2013) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2013.012 · Cited by 23

Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma

Hartsough, E. J., Basile, K. J., & Aplin, A. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0581 · Cited by 24

Metastatic melanoma moves on: translational science in the era of personalized medicine

Levesque, M. P., Cheng, P. F., Raaijmakers, M. I. G., Saltari, A., & Dummer, R. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9658-0 · Cited by 23

ABIN-2, of the TPL-2 Signaling Complex, Modulates Mammalian Inflammation

Webb, L. V., Ventura, S., & Ley, S. C. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.07.001 · Cited by 24

N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production

Malvi, P., Janoštiak, R., Nagarajan, A. G., Zhang, X., & Wajapeyee, N. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101217 · Cited by 26

A twenty year perspective on melanoma therapy

Flaherty, K. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13125 · Cited by 23

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Passeron, T., Lacour, J. ‐., Allégra, M., Ségalen, C., Deville, A., Thyss, A., Giacchero, D., Ortonne, J. P., Bertolotto, C., Ballotti, R., et al. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01385.x · Cited by 23

That which does not kill me makes me stronger; combining ERK 1/2 pathway inhibitors and BH 3 mimetics to kill tumour cells and prevent acquired resistance

Sale, M. J., & Cook, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12220 · Cited by 23

Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway

Liu, S., Yu, H., Kumar, S., Martin, J. S., Bing, Z., Sheng, W., Bosenberg, M., & Xu, X. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.11.18380 · Cited by 23

Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies

Batist, G., Wu, J. H., Spatz, A., Miller, W. H., Cocolakis, E., Rousseau, C., Diaz, Z., Ferrario, C., & Basik, M. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00059 · Cited by 23

MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma

Asundi, J., Lacap, J. A., Clark, S., Nannini, M., Roth, L. A., & Polakis, P. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0446 · Cited by 26

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics

Chen, L., Stuart, L. M., Ohsumi, T. K., Burgess, S. M., Varshney, G. K., Dastur, A., Borowsky, M. L., Benes, C. H., Lacy‐Hulbert, A., & Schmidt, E. V. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-93 · Cited by 23

Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells

Pathria, G., Garg, B., Borgdorff, V., Garg, K., Wagner, C., Superti‐Furga, G., & Wagner, S. N. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.369 · Cited by 23

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma

Kim, H. K., Lee, S., Kim, K., Heo, M. H., Lee, H., Cho, J., Kim, N. K. D., Park, W., Lee, S. J., Kim, H. J., et al. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.09.004 · Cited by 23

Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition

Sharma, R., Smalley, I., Spence, P., Sondak, V. K., Smalley, K. S. M., & Koomen, J. M. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00613 · Cited by 21

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors

Lei, F. X., Jin, L., Liu, X., Lai, F., Yan, X. G., Farrelly, M. L., Guo, S., Zhao, X. H., & Zhang, X. D. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0714-7 · Cited by 23

Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D

Qiang, Z., Zhou, Z., Peng, T., Jiang, P., Shi, N., Njoya, E. M., Azimova, B., Liu, W., Chen, W., Zhang, G., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0971-4 · Cited by 23

Profile of selumetinib and its potential in the treatment of melanoma

Patel, S. P., & Kim, D. W. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s51596 · Cited by 23

Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma

Panka, D. J., Buchbinder, E. I., Giobbie‐Hurder, A., Schalck, A. P., Montaser‐Kouhsari, L., Sepehr, A., Lawrence, D. P., McDermott, D. F., Cohen, R., Carlson, A. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0349 · Cited by 22

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

Mazor, R. D., Weissman, R., Luckman, J., Domachevsky, L., Diamond, E. L., Abdel-Wahab, O. I., Shapira, S., Hershkovitz‐Rokah, O., Groshar, D., & Shpilberg, O. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa024 · Cited by 22

Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors

Zhang, F., Tang, X., Fan, S., Liu, X., Sun, J., Ju, C., Liang, Y., Liu, R., Zhou, R., Yu, B., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01834-1 · Cited by 22

A novel activating JAK1 mutation in chronic eosinophilic leukemia

Shomali, W. E., Damnernsawad, A., Theparee, T., Sampson, D. A., Morrow, Q., Yang, F., Fernandez‐Pol, S., Press, R. D., Zehnder, J. L., Tyner, J. W., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004237 · Cited by 22

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

Kim, J. E., Stones, C. J., Joseph, W. R., Leung, E. Y., Finlay, G. J., Shelling, A. N., Phillips, W. A., Shepherd, P. R., & Baguley, B. C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-141 · Cited by 23

Braf V600E mutation in melanoma: translational current scenario

Guadarrama-Orozco, J. A., Ortega-Gómez, A., Ruíz‐García, E., la Vega, H. A., Meneses-García, A. A., & López‐Camarillo, C. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1469-6 · Cited by 22

The application of proteomics in different aspects of hepatocellular carcinoma research

Xing, X., Liang, D., Huang, Y., Zeng, Y., Han, X., Liu, X., & Liu, J. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.03.050 · Cited by 22

GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax

Vlčková, K., Réda, J., Ondrušová, Ľ., Krayem, M., Ghanem, G., & Vachtenheim, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3596 · Cited by 22

Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma

Feddersen, C. R., Schillo, J. L., Varzavand, A., Vaughn, H. R., Wadsworth, L. S., Voigt, A. P., Zhu, E. Y., Jennings, B. M., Mullen, S. A., Bobera, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0244 · Cited by 25

Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies

Dülgar, Ö., Kütük, T., & Eroglu, Z. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00572-6 · Cited by 23

BRAF and beyond: Tailoring strategies for the individual melanoma patient

Khushalani, N. I., & Jarkowski, A. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.126759 · Cited by 22

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells

Mologni, L., Costanza, M., Sharma, G. G., Viltadi, M., Massimino, L., Citterio, S., Purgante, S., Raman, H., Pirola, A., Zucchetti, M., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.009 · Cited by 21

The role of macrophage migration inhibitory factor family and CD74 in the pathogenesis of melanoma

Tanese, K., & Ogata, D. (2024) · Experimental Dermatology · doi:10.1111/exd.15122 · Cited by 23

Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma

Koomen, J. M., & Smalley, K. S. M. (2011) · Oncotarget · doi:10.18632/oncotarget.263 · Cited by 21

Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression

Huang, H., Wu, Y., Fu, W., Wang, X., Zhou, L., Xu, X., Huang, F., & Wu, Y. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4134 · Cited by 21

KSRP modulates melanoma growth and efficacy of vemurafenib

Liu, W., Chou, C., Liu, S., Crossman, D. K., Yusuf, N., Wu, Y., & Chen, C. (2019) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.06.005 · Cited by 20

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo

Hicks, H. M., McKenna, L. R., Espinoza, V. L., Pozdeyev, N. V., Pike, L. A., Sams, S. B., LaBarbera, D. V., Reigan, P., Raeburn, C. D., & Schweppe, R. E. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23284 · Cited by 21

Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology

Errington, T. M., Denis, A., Allison, A. B., Araiza, R., Aza-Blanc, P., Bower, L. R., Campos, J., Chu, H., Denson, S., Donham, C., et al. (2021) · eLife · doi:10.7554/elife.73430 · Cited by 21

Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?

Capogiri, M., Micheli, A. J. D., Lassaletta, Á., Muñoz, D. P., Coppé, J., Mueller, S., & Stücklin, A. G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1074726 · Cited by 21

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

Chen, W., & Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914837 · Cited by 21

Constitutive Activation of MEK1 Promotes Treg Cell Instability in Vivo

Guo, J., Zhang, J., Zhang, X., Zhang, Z., Wei, X., & Zhou, X. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589192 · Cited by 21

Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy.

Liu, Q.-H., Shi, M.-L., Sun, C., Bai, J., & Zheng, J.-N. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.076 · Cited by 17

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases

Vaidhyanathan, S., Wilken-Resman, B., Ma, D. J., Parrish, K. E., Mittapalli, R. K., Carlson, B. L., Sarkaria, J. N., & Elmquist, W. F. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229393 · Cited by 21

NRAS Mutant Melanoma: An Overview for the Clinician for Melanoma Management

Jenkins, R. W., & Sullivan, R. J. (2016) · Melanoma Management · doi:10.2217/mmt.15.40 · Cited by 24

Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Patel, A. A., García, L. F., Mannella, V., Gammon, L., Borg, T., Maffucci, T., Scatolini, M., Chiorino, G., Vergani, E., Rodolfo, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3230 · Cited by 22

Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma

Duggan, M. C., Stiff, A. R., Bainazar, M. A., Regan, K., Salavaggione, G. N. O., Maharry, S. E., Blachly, J. S., Krischak, M. K., Walker, C. J., Latchana, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704371114 · Cited by 23

AMPK regulates Bcl2-L-13-mediated mitophagy induction for cardioprotection

Murakawa, T., Ito, J., Rusu, M.-C., Taneike, M., Omiya, S., Moncayo, J., Nakanishi, C., Sugihara, R., Nishida, H., Mine, K., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115001 · Cited by 22

Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma

Chung, C., & Reilly, S. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140045 · Cited by 20

Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma

King, J., & Nathan, P. (2014) · Future Oncology · doi:10.2217/fon.14.89 · Cited by 21

Implementing precision medicine initiatives in the clinic

Hollebecque, A., Massard, C., & Soria, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000077 · Cited by 20

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis

Ahn, J., Hwang, S., Cho, H., & Lee, M. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.133 · Cited by 21

Magnetic nanoparticles in theranostics of malignant melanoma

Shevtsov, M. A., Kaesler, S., Posch, C., Multhoff, G., & Biedermann, T. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00868-6 · Cited by 20

Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor

Iida, S., Miki, Y., Ono, K., Akahira, J., Nakamura, Y., Suzuki, T., & Sasano, H. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.11.024 · Cited by 20

Raf‐interactome in tuning the complexity and diversity of Raf function

An, S., Yang, Y., Ward, R. J., Liu, Y., Guo, X., & Xu, T. (2014) · FEBS Journal · doi:10.1111/febs.13113 · Cited by 20

Immuno-oncology from the perspective of somatic evolution

González, S., Volkova, N. V., Beer, P. A., & Gerstung, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.001 · Cited by 20

Altered Prostanoid Signaling Contributes to Increased Skin Tumorigenesis in Tpl2 Knockout Mice

DeCicco-Skinner, K. L., Nolan, S. J., Deshpande, M. M., Trovato, E. L., Dempsey, T., & Wiest, J. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056212 · Cited by 20

Multi-task learning predicts drug combination synergy in cells and in the clinicPreprint

Gilvary, C. M., Dry, J. R., & Elemento, O. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/576017 · Cited by 20

Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma

Natarajan, N., Telang, S., Miller, D. M., & Chesney, J. A. (2011) · Drugs · doi:10.2165/11591380-000000000-00000 · Cited by 19

Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

Beetham, H. G., Griffith, B. G. C., Murina, O., Loftus, A. E. P., Parry, D. A., Temps, C., Culley, J., Muir, M., Unciti‐Broceta, A., Sims, A. H., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0373 · Cited by 20

Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives

Olbryt, M. (2022) · Cancers · doi:10.3390/cancers14092315 · Cited by 19

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies

Rubanov, A., Berico, P., & Hernando, E. (2022) · Cancers · doi:10.3390/cancers14235858 · Cited by 23

Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance

Alyateem, G., Wade, H. M., Bickert, A. A., Lipsey, C. C., Mondal, P., Smith, M. D., Labib, R. M., Mock, B. A., Robey, R. W., & Gottesman, M. M. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00608-z · Cited by 20

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review

Puri, M., Gawri, K., & Dawar, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1141876 · Cited by 19

Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

Nijenhuis, C. M., Haanen, J. B. A. G., Schellens, J. H. M., & Beijnen, J. H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.10.006 · Cited by 19

The Crystal Structure of Cancer Osaka Thyroid Kinase Reveals an Unexpected Kinase Domain Fold

Gutmann, S., Hinniger, A., Fendrich, G., Drückes, P., Antz, S., Mattes, H., Möbitz, H., Ofner, S., Schmiedeberg, N., Stojanovic, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.648097 · Cited by 19

Molecularly targeted therapies for melanoma

Kohn, L. L., & Colegio, O. R. (2013) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2012.05829.x · Cited by 22

Sirt1 induction confers resistance to etoposide-induced genotoxic apoptosis in thyroid cancers

KWEON, K. H., Lee, C. R., Jung, S. J., Ban, E. J., Kang, S., Jeong, J. J., Nam, K., Jo, Y. S., Lee, J., & Chung, W. Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2585 · Cited by 19

Future paradigms for precision oncology

Klement, G. L., Arkun, K., Valík, D., Roffidal, T., Hashemi, A., Klement, C., Carmassi, P., Rietman, E. A., Slabý, O., Mazánek, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9488 · Cited by 19

BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods

O’Brien, O., Lyons, T. G., Murphy, S., Feeley, L., Power, D. G., & Heffron, C. C. B. B. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204367 · Cited by 19

Update on the clinical use of kinase inhibitors in melanoma

Cosgarea, I., Ritter, C., Becker, J. C., Schadendorf, D., & Ugurel, S. (2017) · Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · doi:10.1111/ddg.13321 · Cited by 27

New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling

Erickson, K. E., Rukhlenko, O. S., Posner, R. G., Hlavacek, W. S., & Kholodenko, B. Ν. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.008 · Cited by 21

Genetics and Epigenetics of the Skin Meet Deep Sequence

Cheng, J. B., & Cho, R. J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.436 · Cited by 19

Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Sharma, V., Young, L., Cavadas, M. A. S., Owen, K. A., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.11414 · Cited by 18

A landscape of synthetic viable interactions in cancer

Gu, Y., Wang, R., Han, Y., Zhou, W., Zhao, Z., Chen, T., Zhang, Y., Peng, F., Liang, H., Qi, L., et al. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw142 · Cited by 19

Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma

Raymond, J. H., Aktary, Z., Larue, L., & Delmas, V. (2022) · Cancers · doi:10.3390/cancers14030706 · Cited by 20

Fibroblast growth factor receptor 3‐mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition

Ban, M. J., Byeon, H. K., Yang, Y. J., An, S.-J., Kim, J. W., Kim, J. H., Kim, D., Yang, J., Kee, H. J., & Koh, Y. W. (2018) · Cancer Science · doi:10.1111/cas.13839 · Cited by 18

Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors

Lambo, D. J., Lebedenko, C. G., McCallum, P. A., & Banerjee, I. A. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10430-8 · Cited by 17

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape

Nagel, R., Pataskar, A., Champagne, J., & Agami, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1525 · Cited by 21

Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells

Eum, K., Ahn, S. K., Kang, H., & Lee, M. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1446-0 · Cited by 18

Targeted agents for the treatment of metastatic melanoma

Dancey, J. E., & Monzon (2012) · OncoTargets and Therapy · doi:10.2147/ott.s21259 · Cited by 18

Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells

Li, ‡., Li, Y., Liu, Q., & Wang, A. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s70691 · Cited by 18

Mechanisms and Consequences of Dopamine Depletion-Induced Attenuation of the Spinophilin/Neurofilament Medium Interaction

Hiday, A. C., Edler, M., Salek, A. B., Morris, C. W., Thang, M., Rentz, T. J., Rose, K. L., Jones, L. M., & Baucum, A. J. (2017) · Neural Plasticity · doi:10.1155/2017/4153076 · Cited by 17

Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells

Arafeh, R., Flores, K., Keren‐Paz, A., Maik-Rachline, G., Gutkind, N. E., Rosenberg, S. A., Seger, R., & Samuels, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-16558-0 · Cited by 18

The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer

Zhang, L., Zheng, L., Yang, Q., & Sun, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882940 · Cited by 19

Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation

Jossé, R., Zhang, Y., Giroux, V., Ghosh, A. K., Luo, J., & Pommier, Y. G. (2015) · Marine Drugs · doi:10.3390/md13063625 · Cited by 17

Inhibition of RAS Activation Due to a Homozygous Ezrin Variant in Patients with Profound Intellectual Disability

Riecken, L. B., Tawamie, H., Dornblut, C., Buchert, R., Ismayel, A., Schulz, A., Schumacher, J., Sticht, H., Pohl, K. J., Cui, Y., et al. (2014) · Human Mutation · doi:10.1002/humu.22737 · Cited by 18

The MEK1/2 Inhibitor AS703026 Circumvents Resistance to the BRAF Inhibitor PLX4032 in Human Malignant Melanoma Cells

Park, S., Hong, S., Moon, J.-H., Jin, D.-H., Kim, J., Lee, C., Kim, K., Hong, Y. S., Lee, J. S., Lee, J., et al. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318298a185 · Cited by 18

Prospects for MEK inhibitors for treating cancer

Martín-Liberal, J., Lagares‐Tena, L., & Larkin, J. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.892578 · Cited by 18

Morphological map of under- and overexpression of genes in human cells

Chandrasekaran, S. N., Alix, E., Arévalo, J., Borowa, A., Byrne, P. J., Charles, W. G., Chen, Z., Cimini, B. A., Deng, B., Doench, J. G., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02753-9 · Cited by 21

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244

How melanomas bypass new therapy

Solit, D. B., & Sawyers, C. L. (2010) · Nature · doi:10.1038/468902a · Cited by 51

The Melanoma Rollercoaster Continues: Resistance with B-RAF Inhibitor PLX4032 Takes Unexpected Turn

Tuma, R. S. (2011) · Oncology Times · doi:10.1097/01.cot.0000394490.60274.3e

Getting Around PLX4032: Studies Turn Up Unusual Mechanisms of Resistance to Melanoma Drug

Tuma, R. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr016 · Cited by 13

PLX4032 resistance mechanisms in B-RAF V600E positive melanoma

Kester, L. A. (2012) · Utrecht University Repository (Utrecht University)